What Is IGF-DES Research Material?
IGF-DES research material refers to laboratory research material commonly identified as des(1-3)IGF-I, des(1-3)IGF-1, or IGF-1 DES.
Des(1-3)IGF-I is a truncated variant of human insulin-like growth factor-I in which the N-terminal tripeptide Gly-Pro-Glu is absent. Published research has identified this form in biological materials and has investigated its biochemical and cellular properties.
This structural difference is important because the N-terminal region of IGF-I participates in interactions with IGF-binding proteins. Research has shown that removing the first three residues substantially alters binding characteristics compared with intact IGF-I.
For researchers, therefore, IGF-DES is best understood as a
, not simply another commercial name for full-length IGF-I.
A scientifically responsible research-material page should focus on:
- Molecular identity
- Structural differences
- Peptide sequence
- Analytical characterization
- Purity
- Batch documentation
- Certificate of Analysis
- Research applications
- Distinction from other IGF analogues
This approach also creates useful SEO coverage for searches such as IGF-DES research material, IGF-DES research peptide, DES(1-3)IGF-1, and IGF-1 DES.
IGF-DES Research Material at a Glance
| Attribute | Research Information |
|---|---|
| Common designation | IGF-DES |
| Scientific designation | des(1-3)IGF-I / des(1-3)IGF-1 |
| Parent molecule | Human IGF-I |
| Structural modification | N-terminal Gly-Pro-Glu deletion |
| Mature IGF-I length | 70 amino acids |
| Des(1-3)IGF-I length | 67 amino acids |
| Research category | IGF / protein research |
| Key research interest | Structure, binding and cellular signaling |
| Analytical approaches | HPLC, mass spectrometry, sequence/identity testing |
| Documentation | Batch-specific COA recommended |
| Research context | Laboratory and scientific investigation |
Published literature describes mature human IGF-I as a 70-amino-acid single-chain polypeptide and des(1-3)IGF-I as its N-terminally truncated form.
Understanding DES(1-3)IGF-1
The name DES(1-3)IGF-1 describes the structural modification directly.
The first three amino acids of mature IGF-I are:
Glycine – Proline – Glutamate
or:
Gly-Pro-Glu
In des(1-3)IGF-I, these three residues are absent.
Consequently, the molecule contains the remaining portion of the mature IGF-I sequence, producing a 67-amino-acid truncated form.
The scientific significance extends beyond the difference in residue count. Research has demonstrated that the N-terminal deletion can substantially affect interactions with IGF-binding proteins. For example, experimental studies have reported markedly reduced binding affinity for certain IGFBPs compared with intact IGF-I.
This makes IGF-DES useful in comparative research examining how a relatively small sequence modification can change protein-protein interactions.
IGF-DES Research Material vs. Full-Length IGF-I
A major consideration when evaluating IGF-DES research material is ensuring that it is not confused with full-length IGF-I.
Full-Length IGF-I
Mature human IGF-I contains approximately 70 amino acids and has the complete mature N-terminal sequence.
IGF-DES
Des(1-3)IGF-I lacks the N-terminal Gly-Pro-Glu tripeptide and is therefore 67 amino acids long.
The difference can influence interactions with IGF-binding proteins.
Research using biosensor methods has reported that des(1-3)IGF-I has substantially lower affinity for IGFBP-3 than intact IGF-I.
Other research has similarly used des(1-3)IGF-I as a comparative molecule when studying IGF-binding-protein interactions.
Therefore, laboratories should not treat the following as interchangeable:
- IGF-DES
- Full-length IGF-I
- IGF-1 LR3
- Other IGF-I fragments
- IGF-II
- Other modified IGF analogues
The exact molecular identity should always be established before analytical or comparative work.
Why Molecular Identity Matters
The phrase IGF-DES research material describes a research subject, but the phrase alone is not sufficient to establish every molecular property of a particular commercial preparation.
Researchers should verify:
- Exact product designation
- Amino-acid sequence
- Molecular form
- Expected molecular mass
- Purity specification
- Analytical method
- Batch or lot number
- Certificate of Analysis
This is especially important for IGF-related materials because small structural modifications can create substantially different biochemical behavior.
A page describing IGF-DES should therefore avoid automatically assigning specifications from full-length IGF-I or from unrelated IGF analogues.
IGF-DES Peptide Sequence
Sequence information is one of the most useful technical characteristics of IGF-DES research material.
The defining feature is the deletion of residues 1–3 from mature IGF-I.
Simplified comparison
Mature IGF-I:
Residues 1–70
Des(1-3)IGF-I:
Residues 4–70
The first three residues are:
Gly-Pro-Glu
The resulting truncated molecule is generally described as a 67-amino-acid form of IGF-I.
For a product-specific page, the exact sequence should be confirmed against the manufacturer’s technical documentation or analytical certificate rather than relying exclusively on a third-party database.
This is particularly important when comparing research materials from different suppliers.
IGF-DES Molecular Structure
IGF-I belongs to the insulin-like growth factor family of single-chain polypeptides. Published structural reviews describe IGF-I as containing B, C, A, and D domains and emphasize the importance of its molecular architecture for interactions with receptors and binding proteins.
IGF-DES retains the overall IGF-I framework while lacking the N-terminal three-residue segment.
The resulting structural modification provides researchers with an experimental model for investigating questions such as:
- How does the IGF-I N-terminus influence binding?
- How do sequence changes affect IGFBP interactions?
- How does ligand structure affect receptor-related experiments?
- How does molecular truncation influence protein availability?
- How can analytical techniques distinguish related IGF forms?
This makes structure an important component of any high-quality IGF-DES research-material page.
IGF-DES Molecular Weight
Searches for IGF-DES molecular weight should be handled carefully.
Theoretical molecular mass depends on the precise molecular composition and calculation convention. Researchers may encounter:
- Average molecular weight
- Monoisotopic mass
- Calculated molecular mass
- Experimental mass
- Mass associated with a specific molecular form
The most useful value for a specific research material should be supported by the exact sequence and analytical documentation.
Mass spectrometry can provide experimental evidence for molecular identity and can help distinguish the expected truncated molecule from related products or degradation species.
A product page should therefore avoid presenting a molecular-weight value copied from full-length IGF-I as the molecular weight of IGF-DES.
IGF-DES Research Applications
The scientific literature provides several research contexts in which des(1-3)IGF-I has been investigated.
1. IGF Structure Research
IGF-DES provides a useful comparison for studying how removal of an N-terminal sequence changes the properties of a protein.
2. IGF-Binding Protein Research
One of the best-established research interests involves interactions between IGF-DES and IGF-binding proteins.
Studies have reported reduced binding affinity of des(1-3)IGF-I for several IGFBPs compared with intact IGF-I.
3. Receptor-Interaction Research
IGF-related molecules have been studied in receptor-binding experiments to understand ligand-receptor interactions and how molecular modifications affect these processes.
4. Cell-Based Research
Published experiments have investigated truncated IGF-I in cultured-cell models and compared its biological behavior with intact IGF-I.
5. Comparative Protein Research
Researchers can compare IGF-DES with full-length IGF-I to investigate relationships between sequence, protein binding, and cellular responses.
6. Analytical Chemistry
IGF-DES can also be investigated using analytical workflows designed to establish molecular identity and purity.
These research applications should be described as scientific research contexts rather than therapeutic recommendations.
IGF-DES and IGF-Binding Proteins
The relationship between IGF-DES and IGF-binding proteins is one of the most important scientific reasons for studying this truncated molecule.
IGF-binding proteins regulate the availability and interactions of IGF molecules in biological systems.
Research has found that removing the N-terminal Gly-Pro-Glu region markedly reduces the affinity of des(1-3)IGF-I for several binding proteins. A Journal of Biological Chemistry study reported substantially lower affinity of des(1-3)IGF-I for IGFBP-3 than for intact IGF-I.
Other studies have also used des(1-3)IGF-I as a low-binding-affinity comparator in IGFBP experiments.
This makes IGF-DES a useful research model for examining how a protein’s N-terminal sequence contributes to molecular recognition.
IGF-DES Analytical Testing
Analytical characterization is central to evaluating research material.
HPLC
High-performance liquid chromatography can be used to assess chromatographic purity and identify major components within a sample.
A useful HPLC report should ideally identify:
- Analytical method
- Column or separation approach
- Detection method
- Retention time
- Main peak
- Reported purity
Mass Spectrometry
Mass spectrometry can help determine whether the observed molecular mass is consistent with the expected molecular structure.
For IGF-DES, this is particularly useful when distinguishing:
- Des(1-3)IGF-I
- Full-length IGF-I
- Truncated variants
- Oxidized species
- Degradation products
- Unexpected molecular forms
Sequence or Identity Testing
Where available, sequence-related characterization can provide additional confirmation that the research material corresponds to the stated molecule.
Using several complementary analytical methods generally provides stronger evidence than relying on a single measurement.
IGF-DES Certificate of Analysis
A Certificate of Analysis (COA) is an important document when evaluating IGF-DES research material.
A useful COA should ideally identify the specific batch and provide relevant analytical information.
Recommended COA fields
- Product name
- Product identifier
- Batch/lot number
- Test date
- Appearance
- Purity
- HPLC result
- Mass-spectrometry result
- Identity testing
- Storage information
- Testing laboratory
The COA should correspond to the actual lot under consideration.
Researchers should be cautious about generic certificates that cannot be connected to a specific batch.
A strong research-material page can also explain that a COA is supporting analytical documentation, rather than a guarantee that a material is suitable for every experimental protocol.
IGF-DES Research Material: Quantity vs. Purity
Product quantity and product purity are different characteristics.
For example, an IGF-DES 2mg product describes the stated quantity of material.
It does not mean:
- 2mg of a different molecular form
- A different sequence
- A different analogue
- A different molecular weight
Similarly, a stated purity percentage does not replace identity confirmation.
A useful product evaluation therefore considers both:
Quantity + Identity + Purity + Documentation
This distinction is valuable for users searching for both commercial information and technical research data.
How to Evaluate IGF-DES Research Material
Before selecting research material, researchers can review several documentation categories.
1. Molecular identity
Does the documentation clearly identify the material as des(1-3)IGF-I?
2. Sequence
Does the documented sequence correspond to the stated truncated form?
3. Purity
Is a quantitative purity result provided?
4. Analytical evidence
Are HPLC or mass-spectrometry results available?
5. Batch information
Can the COA be connected to a specific lot?
6. Storage information
Does the documentation provide appropriate research-material storage information?
7. Research-use designation
Is the material clearly separated from approved pharmaceutical products?
These factors provide a more useful evaluation framework than relying on product naming alone.
IGF-DES vs. IGF-1 LR3
A common source of confusion online is treating all modified IGF-related research materials as equivalent.
They are not.
IGF-DES is characterized by deletion of the N-terminal Gly-Pro-Glu sequence.
IGF-1 LR3 represents a different engineered IGF-I analogue with different structural modifications.
Because the molecules are structurally distinct, they should have separate technical profiles, analytical expectations, and product documentation.
For SEO architecture, this also means creating separate pages rather than combining several different IGF-related materials into a single generic page.
IGF-DES Research Material and Scientific Literature
Des(1-3)IGF-I has a substantial historical research literature.
A foundational review published in 1996 described it as a truncated form of IGF-I lacking the N-terminal Gly-Pro-Glu sequence and summarized research concerning its altered interactions with IGF-binding proteins.
Earlier research also characterized recombinant truncated IGF-I and compared its biological activity and binding characteristics with intact IGF-I.
Subsequent studies have continued using des(1-3)IGF-I as an experimental molecule in investigations of IGFBP interactions and IGF-related cellular biology.
For an SEO page, linking the topic to the scientific literature adds useful informational depth while keeping product claims separate from experimental findings.
Research-Use Positioning
IGF-DES research material should be described specifically as a laboratory research material.
The page should not imply that experimental observations establish human therapeutic efficacy or safety.
Research performed in cultured cells, animal models, or biochemical systems provides scientific information about molecular behavior in those particular experimental conditions. It should not automatically be generalized to human use.
This distinction is particularly important because historical publications report enhanced biological activity of des(1-3)IGF-I in certain experimental systems. Those observations are scientifically relevant, but they do not constitute a recommendation for human administration.
Frequently Asked Questions
What is IGF-DES research material?
IGF-DES research material generally refers to des(1-3)IGF-I, a truncated form of IGF-I lacking the N-terminal Gly-Pro-Glu tripeptide.
What does DES(1-3)IGF-1 mean?
The designation indicates that amino-acid residues 1 through 3 of mature IGF-I have been removed.
How many amino acids are in IGF-DES?
Des(1-3)IGF-I is generally described as a 67-amino-acid form compared with 70 amino acids in mature IGF-I.
Is IGF-DES the same as IGF-1?
No. IGF-DES is an N-terminally truncated form of IGF-I, while full-length IGF-I retains the complete mature sequence.
Is IGF-DES the same as IGF-1 LR3?
No. IGF-DES and IGF-1 LR3 are different IGF-related molecules with different structural modifications.
What should an IGF-DES COA contain?
A useful COA should identify the product and batch and ideally include purity and identity information supported by analytical techniques such as HPLC and mass spectrometry.
Why is IGF-DES studied?
Researchers study IGF-DES to investigate how N-terminal structural changes influence IGF-binding proteins, molecular interactions, cellular responses, and other aspects of IGF biology.
Does IGF-DES have a different molecular weight from IGF-I?
Yes. Removing three amino acids changes the molecular mass. However, the exact value should be calculated from the verified molecular form and sequence and confirmed against appropriate analytical documentation.
Is IGF-DES research material intended for human use?
Research material should be presented exclusively for laboratory and scientific research and should not be represented as an approved human therapeutic product.